巨细胞性心肌炎的诊治进展  

Giant cell myocarditis

作　　者：刘琳[1] 丁文惠[1] Liu Lin;Ding Wenhui(Department of Cardiology,Peking University First Hospital,Beijing 100034,China)

机构地区：[1]北京大学第一医院心内科,北京100034

出　　处：《中华心力衰竭和心肌病杂志（中英文）》2022年第4期335-339,共5页Chinese Journal of Heart Failure and Cardiomyopathy

摘　　要：巨细胞性心肌炎(GCM)是一种罕见的、致命的特发性心肌炎,多发生在中青年,以心力衰竭、心律失常、猝死为主要表现。GCM确诊一般需要病理检查。患者预后极差,死亡及心脏移植发生率很高,早期确诊并开展针对性的免疫抑制治疗,可以改善患者预后。本文介绍巨细胞心肌炎在诊断和治疗方面的进展。Giant cell myocarditis(GCM)is rare and fatal idiopathic myocarditis,mainly affected young and middle-aged people,which can lead to heart failure,arrhythmia and sudden death.Diagnosis of GCM usually requires pathological examination.The prognosis of patients with GCM is very poor,with a high incidence of death and heart transplantation.Early diagnosis and targeted immunosuppressive therapy can improve the prognosis of patients.This article will introduce the progress in the diagnosis and treatment of GCM.

关 键 词：巨细胞性心肌炎 心内膜心肌活检 

分 类 号：R542.21[医药卫生—心血管疾病]